Everolimus and rapamycin, as main mTOR pathway inhibitors, have greater oral bioavailability and favorable pharmacokinetics.[21,22] Therapeutic effect of Everolimus and rapamycin is effective on tumors, but remains to be studied on neurological symptoms.[23] The prevalence of epilepsy in patients with TSC approximates 75% to 90% across the lifetime, and it is usually medically refractory epilepsy.[24] The patients with medically refractory epilepsy still have seizures after taking mTOR inhibitors treatment, such as proband and I1. The gene discussed is MTOR; the disease is epilepsy.